SEC Form 4 · accession 0001209191-18-037138
ACORDA THERAPEUTICS INC · ACOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lauren M Sabella
Officer — Chief Commercial Officer
Period of report
Jun 8, 2018
Accepted (ET)
Jun 12, 2018 · 7:40 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001008848
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 8, 2018 | M | 24,375 | $16.50 | A | 35,540 | D | |
| Common StockF1 | Jun 8, 2018 | S | 24,375 | $35.00 | D | 11,165 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F2 | $16.50 | Jun 8, 2018 | M | 24,375 | D | — | May 1, 2027 | Common Stock | 24,375 | 40,625 | D |
Explanation of responses
- F1Exercise and sale pursuant to a 10b5-1 plan.
- F2The shares subject to this option vest over two years from the May 1, 2017 grant date, with the first 25% having vested at the end of six months after the grant date and the remaining 75% vesting in equal quarterly installments over the remainder of such two year period.